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Abstract Recently, fragments of extracellular proteins, includ-
ing endostatin, were defined as a novel group of angiogenesis
inhibitors. In this study, human plasma equivalent hemofiltrate
was used as a source for the purification of high molecular weight
peptides (10^20 kDa), and the isolation and identification of
circulating human endostatin are described. The purification of
this C-terminal fragment of collagen K1(XVIII) was guided by
MALDI-MS and the exact molecular mass determined by ESI-
MS was found to be 18 494 Da. N-terminal sequencing revealed
the identity of this putative angiogenesis inhibitor and its close
relation to mouse endostatin. The cysteine residues 1^3 and 2^4
in the molecule are linked by disulfide bridges. In vitro biological
characterization of the native protein demonstrated no anti-
proliferative activity on different endothelial cell types. These
data indicate that human endostatin, which is a putative
angiogenesis inhibitor, is present in the circulation.
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1. Introduction
A crucial step in tumor progression and metastasis is the
vascularization of the tumor and its immediate surroundings
[1,2] through the interaction of pro- and anti-angiogenic fac-
tors. The induction of angiogenesis is mediated by angiogenic
factors such as the ¢broblast growth factors, and the factors
related to vascular endothelial growth factor/vascular perme-
ability factor [3,4]. In addition, several negative regulators of
angiogenesis have been identi¢ed [5], e.g. platelet factor 4,
interferon K, thrombospondin, and angiopoietin 2 [6]. More-
over, polypeptide angiogenesis inhibitors generated by a pri-
mary tumor were shown to inhibit its metastasis [7,8]. In this
respect, angiostatin or endostatin was isolated from cell cul-
ture medium [9,10], and shown to speci¢cally inhibit prolifer-
ation of endothelial cells and consequently tumor growth and
metastasis in di¡erent animal models. Mouse endostatin,
which entails a C-terminal 20 kDa fragment of collagen XVIII
[11], in combination with angiostatin, the kringle-containing
fragment of plasminogen [10], exhibited potent tumor inhib-
itory activity.
Using a human peptide bank including at least 300 000
peptide components generated from hemo¢ltrate of patients
with chronic renal diseases [12] we were able to isolate and
characterize di¡erent bioactive peptides. Most of these pep-
tides identi¢ed so far are proteolytic products of plasma com-
ponents [13]. For example, bioactive RGD peptides from vi-
tronectin and ¢brinogen [14,15], proteolytic fragments of
plasma albumin, haptoglobin or L2-microglobulin were puri-
¢ed in high amounts. During the course of de¢ning and char-
acterizing high molecular weight peptides of this human pep-
tide bank (in the range 10^20 kDa), which strongly bind to
cation exchangers, we isolated the circulating form of human
endostatin which was previously described from mouse origin
and was shown to be a potent angiogenesis inhibitor in vivo
[10]. Our ¢ndings indicate that endostatin is present in the
circulation of patients not bearing any detectable tumor.
2. Materials and methods
2.1. Isolation of endostatin from human hemo¢ltrate
Human blood ultra¢ltrate (hemo¢ltrate, HF) was obtained from
patients with chronic renal insu⁄ciency. Hemo¢lters with a cut-o¡
of 20 kDa were used and the ¢ltrate was immediately acidi¢ed with
HCl to pH 3.0 and cooled to inhibit proteolysis. Peptides from 2500 l
HF were extracted and processed as described [12]. In brief, the ex-
tracts were pooled for the ¢rst separation step using a 10 l cation
exchange column. Stepwise batch elution was performed using seven
bu¡ers with di¡erent pHs (increasing from 3.6 to 9.0; pools 1^7). An
additional pool 8 was generated by washing the column with water,
pH 7.0. The resulting eight pools (15^25 l each) were further separated
using reverse phase chromatography. Pool 8 was applied to a RP-C18
column (15^20 Wm, 30 nm, 4.7U30 cm; Vydac, Hesperia, USA), and
separation was performed at a £ow rate of 35 ml/min with a gradient
from 100% A to 50% B in 30 min (A: water, 10 mM HCl; B: 100%
methanol, 10 mM HCl). Fractions of 1.4 min were collected, monitor-
ing the absorbance at 280 nm. Aliquots were subjected to matrix-
assisted laser desorption ionization mass spectrometry (MALDI-
MS). The next puri¢cation step was carried out with an analytical
RP-C18 column (5 Wm, 30 nm, 1.0U25 cm; Vydac; £ow rate: 2 ml/
min) using the following gradient and bu¡ers: from 100% A (water,
0.1% tri£uoroacetic acid) to 60% B (80% acetonitrile, 0.1% tri£uoro-
acetic acid) in 50 min. Fractions of 1 min were collected and those
peaks containing the peptide with a molecular mass of 18.5 kDa were
rechromatographed at a £ow rate of 0.6 ml/min by analytical RP-C18
(5 Wm, 30 nm, 0.46U25 cm; YMC, Schernbeck, Germany) using the
same RP bu¡ers. A gradient from 30% to 80% B in 150 min was
applied to obtain highly puri¢ed endostatin. To check the purity of
the isolated peptides, capillary zone electrophoresis was carried out as
described [16].
2.2. Peptide analysis and synthesis
Mass determination of the puri¢ed peptides was carried out on a
Sciex API III+ quadrupole mass spectrometer (Sciex, Thornhill, Can-
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ada) with an electrospray interface (ESI-MS) as described [16]. Colli-
sion-induced dissociation of peptides obtained from proteolytic di-
gests (ESI-MS/MS analysis) was performed with argon gas and inter-
preted with the help of ‘Sherpa’ [17]. The peptides were further
analyzed by a Procise 494 gas-phase sequencer (Applied Biosystems,
Weiterstadt, Germany). For MALDI-MS, aliquots of 1 Wl of the
samples from the reverse phase chromatography, representing a 5 ml
hemo¢ltrate equivalent, were applied on a stainless steel multiple sam-
ple tray and mixed with either sinapinic acid or K-cyanohydroxy-
cinnamic acid using the dried drop technique as described [18]. For
analysis of cysteines, lyophilized peptides were reduced with 2-mer-
captoethanol and alkylated at cysteine residues with iodoacetamide
using standard conditions. The carboxamido-methyl-alkylated pep-
tides (AcNH2 peptides) and generated tryptic fragments were puri¢ed
by RP-HPLC and analyzed by mass spectrometry. Proteolytic cleav-
age of aliquots containing about 250 pmol native and AcNH2 pep-
tides was performed by thermolysin, chymotrypsin, Glu-C, and tryp-
sin, respectively (Boehringer Mannheim, Germany) using standard
conditions as recommended by the manufacturer. Successful diges-
tions were separated in a linear acetonitrile gradient by analytical
RP-C18 column. Peptide synthesis of HTHQDFQPVLHL amide
was carried out on a 9050 peptide synthesizer using a preloaded
Rink-amid resin (PerSeptive Biosystems, Wiesbaden, Germany) using
conventional Fmoc chemistry. Purity and identity of the peptide were
checked by HPLC, capillary zone electrophoresis, and electrospray
mass spectrometry.
2.3. Endothelial cell proliferation assays
Bovine brain capillary endothelial cells were isolated as described
[19] and kindly provided by Dr. L. Schweigerer (Essen, Germany).
Human umbilical vein endothelial cells (HUVEC) were isolated as
described [20]. Both cell types were cultured in endothelial cell me-
dium MCDB 131 from PromoCell (Heidelberg, Germany), containing
2.5% fetal calf serum, and basic ¢broblast growth factor (2 ng/ml) on
gelatin-coated plates. Cells (30 000/well) were seeded in gelatin-coated
48-well plates in complete medium, and the next day the medium was
replaced with fresh medium without any basic ¢broblast growth fac-
tor. Endostatin (0^50 nM) was added to cells for 30 min before the
addition of 4 ng/ml basic ¢broblast growth factor. After incubation
for 4 days the cells were trypsinized and counted in an electronic
counter (Schaºrfe System, Reutlingen, Germany). A total of ¢ve ex-
periments were performed each using three separate preparations of
endostatin.
3. Results and discussion
3.1. Peptide isolation and biochemical characterization of
endostatin
An established large-scale method for peptide preparation
from human blood, generating a bank of circulating human
peptides, was used to isolate endostatin [12]. Chromato-
graphic methods in combination with MALDI-MS were
used to purify high molecular weight basic peptides within a
molecular range of 10^20 kDa and the isolation of highly
puri¢ed endostatin from a crude mixture was performed via
a four-step puri¢cation scheme (Fig. 1). Using MALDI-MS,
peptides occurring in the lower picomolar range were detect-
able in very complex mixtures and are suitable for puri¢cation
as demonstrated previously [18]. Initially, hemo¢ltrate was
fractionated via cation exchange chromatography into pH
pools containing peptides with di¡erent basicity and/or pI
(Fig. 1A). Further fractionation of pool 8 was performed by
RP chromatography and yielded several fractions which were
examined by MALDI-MS. Major components of the marked
fraction (Fig. 1B) had molecular masses of 25, 21, 11.7, and
10.5 kDa, while signals at 18.5 and 12.5 kDa were just detect-
able (Fig. 1C). Puri¢cation of the high molecular weight pep-
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Fig. 1. Puri¢cation of human circulating endostatin from hemo¢ltrate guided by MALDI-MS. A: Preparative cation exchange chromatography
and pH pool fractionation of 2500 l human hemo¢ltrate. In pool 8 high molecular weight peptides were detected and subsequently puri¢ed by
several chromatographic steps. B: RP-HPLC fractionation of pH pool 8. High molecular weight peptides were detected in the marked fraction
using MALDI-MS. C: MALDI-MS scan of the fraction marked in B. K1-Microglobulin (K1Mg), retinol binding protein (RbP), endostatin
(Endo), and L2-microglobulin (L2Mg) were detected. D: Puri¢cation of human circulating endostatin was performed using two additional RP-
HPLC steps. The purity of the peptide was demonstrated by capillary zone electrophoresis.
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tides was performed by subsequent RP chromatography (data
not shown) and was guided by MALDI-MS. Substances were
isolated with high purity, as evidenced by capillary zone elec-
trophoresis (Fig. 1D). Sequencing of the puri¢ed peptides de-
rived from one single fraction of RP chromatography (Fig.
1B) revealed the existence of human circulating endostatin
(Mr 18.5 kDa), L2-microglobulin (Mr 11.7 kDa), retinol-bind-
ing protein (Mr 21 kDa), and partially deglycosylated K1-mi-
croglobulin (Mr 25 kDa). These polypeptides exhibit a basic
or neutral pI and their masses were con¢rmed by ESI-MS
(exempli¢ed in Fig. 2A).
For a more detailed characterization, circulating human
endostatin was isolated in larger amounts from 2500 l of
hemo¢ltrate which yielded 200 Wg of pure polypeptide. Se-
quencing of the N-terminal 60 residues (Fig. 2B) as well as
proteolytic digestion of the native and amido-alkylated pep-
tide in conjunction with MALDI-MS, ESI-MS, and MS/MS
analysis revealed high homology to the recently described
mouse endostatin. Native endostatin showed high resistance
against endoproteases Glu-C and chymotrypsin, whereas tryp-
sin led to partial degradation. A tryptic map of the reduced
and amido-alkylated peptide (Fig. 2B) clearly demonstrated
that human endostatin comprises amino acids 514^683 of
the human collagen K1(XVIII) sequence deduced from
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Fig. 2. Identi¢cation of human circulating endostatin as collagen K1(XVIII) 514^683. A: Mass determination of the native endostatin using
electrospray mass spectrometry. The mass spectrum consists of four di¡erent ion species with m/z ratios of 1682.4, 1849.4, 2056.2, and 2312.6
representing multiple charged ions of the peptide. The molecular mass of the native peptide was determined to be 18 494 þ 2.1 Da. B: Sequence
analysis and enzymatic digest of human endostatin. Sixty residues of the N-terminus were sequenced (broken line). Native and reduced AcNH2
peptide were cleaved by trypsin (T). The resulting fragments were analyzed by MALDI-MS (solid lines). The cysteine containing regions in the
native molecule show high stability against trypsin. Determination of the two disul¢de bonds (bold lines) was performed by ESI-MS/MS analy-
sis of peptides derived from thermolytic digest of the native endostatin molecule. C: Analysis of disul¢de bonds of endostatin by ESI-MS/MS.
Peptides from thermolytic digest were separated by RP-HPLC, and subsequent ESI-MS/MS analysis of the peptide with Mr 1088 (parent ion,
amino acids boxed and shaded in B) and some fragment ion signals are shown with their deduced sequences. The parent ion mass and its frag-
ment pattern were in accordance with the amino acid sequence corresponding to residues 122^125 and 159^163 of human endostatin from he-
mo¢ltrate. In the region of the immonium ion and dipeptides, all single amino acid (except Y and C) residues and several dipeptides were de-
tected with the proposed sequence (data not shown).
Fig. 3. N-terminal sequences of human circulating endostatin and mouse endostatin. The sequences from the non-triple-helical C-terminal re-
gions of collagen K1(XVIII) (schematic drawing) indicate high homology, mismatches between the mouse [10] and human sequences are de-
noted by X. The pre-N-terminal sequences are in italics. The lacking C-terminal lysine (K) in the human sequence is in bold. Note that the hu-
man endostatin isolated from hemo¢ltrate lacks 12 N-terminal amino acids, as compared to the mouse counterpart.
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cDNA [11] with a C-terminal Ser residue. One fragment (Mr
2881) of the tryptic map exactly corresponded to the C-termi-
nal amino acids 145^170 of the molecule (Fig. 2B). In com-
parison to the full cDNA sequence, the C-terminus of human
endostatin lacks a single lysine residue as deduced by mass
spectrometry, indicating possible processing by carboxypepti-
dase(s) (Fig. 3). The alignment with mouse endostatin, iso-
lated from mouse hemangioendothelioma cell medium [10],
indicates that the N-terminus of circulating human endostatin
is 12 amino acids shorter than endostatin from mouse tumors
(Fig. 3). This di¡erence might be explained by di¡erent releas-
ing mechanisms from the parent collagen K1(XVIII) by as yet
unknown protease(s). The pre-N-terminal regions of proc-
essed mouse and human endostatin (Fig. 3) consist of hydro-
phobic amino acids indicating a chymotryptic-like cleavage
site. The human and mouse protein sequences show 86% iden-
tity and s 90% similarity, demonstrating a high structural
(and possibly functional) relationship. Comparison of the
tryptic digests of native and alkylated endostatin consisting
of 170 amino acids indicated stabilization by two disul¢de
bonds. Thermolytic digest revealed a fragment with a molec-
ular mass of 1087.4 Da identi¢ed as (122YCET125)-S-S-
(159VLCIE163) by ESI-MS/MS (Fig. 2C). This indicates that
disul¢de bridges are linked between Cys-123/Cys-161 and Cys-
21/Cys-153. The molecular mass of the native molecule deter-
mined by electrospray mass spectrometry (Fig. 2A) was
18 494 þ 2 Da and is thus exactly in accordance with the cal-
culated mass of amino acids 514^683 from collagen K1(XVIII)
sequence (18 496 Da) deduced from cDNA (supposing that
the cysteines are bridged).
Collagen K1(XVIII) consists of multiple collagenous do-
mains which are separated and £anked by non-triple-helical
regions [21,22]. The endostatin sequence comprises the C-ter-
minal non-triple-helical region of the collagen molecule (Fig.
3). For the mouse endostatin region one potential glycosyla-
tion site was proposed [21]. However, there is no consensus
sequence (XXSer-GlyXX) for attachment of glycosaminogly-
cans within the corresponding human sequence. A similar
structure and about 60% identity at the amino acid level
were shown for the mouse collagen K1(XVIII) and human
collagen K1(XV) sequences, with the conserved pattern of
four cysteine residues in the C-terminal (endostatin) region
[21], suggesting the possible existence of corresponding endo-
statin molecules.
Collagen K1(XVIII) was classi¢ed as a class of non-¢brillar
proteins of the extracellular matrix and was shown to be lo-
calized in vascular basement membrane zones of various or-
gans [22]. In this context the release of an angiogenesis inhib-
itor like endostatin from vessel sites refers to a paracrine
regulation of neovascularization. In contrast, our ¢ndings
provide evidence for circulating endostatin functioning in an
endocrine fashion.
3.2. Functional characterization of endostatin
Based on the experience with several other peptide isola-
tions from hemo¢ltrate carried out previously, the recovery
during puri¢cation was estimated to be in the range of 20%
resulting in a concentration of s 10311 M in hemo¢ltrate.
Considering the cut-o¡ (20 kDa) of the hemo¢lters used, the
concentration of endostatin in (patient) plasma was in the
range of 10310 M or higher. It remains to be established
whether an additional pool of tissue-bound endostatin exists,
as was proposed for angiostatin [23]. A speci¢c ELISA or
RIA is needed to determine this parameter more precisely.
The reported concentrations for anti-proliferative e¡ects of
mouse endostatin on endothelial cells are in the range of
s 3U1039 M or higher [10].
Native endostatin was tested in proliferation assays using
endothelial cells from human umbilical vein or bovine brain
capillaries. Basic ¢broblast growth factor induced stimulation
of cell proliferation on both cell types (Fig. 4). Human endo-
statin showed no anti-proliferative e¡ect on microcapillary
endothelial cells (Fig. 4A), and no e¡ect of endostatin was
detected on HUVEC (Fig. 4B). Since the human peptide is
12 amino acids shorter than the mouse peptide, the dodeca-
peptide mouse sequence was synthesized by solid phase chem-
istry and tested in both systems. In both assays, no e¡ect of
the peptide on endothelial cell proliferation was observed
(data not shown). The conditions of the assays were identical
to those used to test endostatin in the original report [10].
Some di¡erences between our results and previously pub-
lished data in the mouse system are apparent and need to be
addressed: (i) mouse and human endostatin were isolated
from di¡erent sources and thus may have di¡erent properties
regarding selectivity or speci¢city. Moreover, the e⁄cacy of
mouse endostatin in vivo or in vitro may not be duplicated by
the human counterpart. (ii) Mouse and human peptides may
undergo di¡erent posttranslational processing events that are
crucial for their respective biological activity. (iii) Human en-
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Fig. 4. The e¡ect of human endostatin on endothelial cell prolifera-
tion. Bovine brain retinal capillary endothelial cells (A) or human
umbilical vein endothelial cells (B) were pretreated with the indi-
cated concentrations of human endostatin for 30 min. To these pre-
treated cells was added either 4 ng/ml basic ¢broblast growth factor
(dark bars) or saline (light bars) as a control. After 4 days, the wells
were trypsinized and the cell number was determined. Results are
expressed as number of cells per well divided by 1000 (mean þ
S.E.M.). Similar results were obtained in three separate experiments
with each cell type.
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dostatin may not necessarily inhibit endothelial cell prolifer-
ation but can (indirectly) in£uence other cellular functions
needed for angiogenesis which are only prominent in a com-
plex in vivo system. Additional experiments also including
production of recombinant forms of human endostatin are
being currently undertaken to characterize the cellular inter-
actions of this putative angiogenesis inhibitor.
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